• 1.上海華東醫(yī)院普外科（上海200040）;;
  • 2.復(fù)旦大學(xué)華山醫(yī)院普外科（上海200040）;

目的  探討β-catenin（連環(huán)素）在胰腺癌表達的臨床意義。
方法  對手術(shù)切除的46例胰腺癌標本進行免疫組化染色，檢測β-catenin在胰腺癌中的表達，并分析其和胰腺癌的分級、分期以及有無轉(zhuǎn)移等指標的關(guān)系。
結(jié)果  β-catenin在胰腺癌細胞膜的異常表達率為54.3%，且分化越差則在細胞膜的異常表達率越高，有轉(zhuǎn)移者高于無轉(zhuǎn)移者； 其在細胞漿的異常表達率為21.7%，與胰腺癌的分化、分期及有無轉(zhuǎn)移無顯著相關(guān)性，但23例術(shù)前介入化療的患者中，腫塊縮小者（14例）在細胞漿的異常表達率為0，顯著低于9例腫塊無縮小者的33.3%； β-catenin在細胞膜和細胞漿異常表達具有一致性，為63.0%。
結(jié)論  β-catenin在細胞膜的異常表達能促進腫瘤轉(zhuǎn)移，在細胞漿內(nèi)的異常表達可能會促進腫瘤細胞的增殖。

引用本文： 孫建,倪泉興,傅德良,虞先俊,姚琪遠,張延齡. β-catenin在胰腺癌中表達的意義. 中國普外基礎(chǔ)與臨床雜志, 2004, 11(5): 440-441. doi: 復(fù)制

1. Klppel G, Maillet B. Classification and staging of pancreatic nonendocrine tumors [Ｊ]. Radiol Clin North Am， 1989; 27(1)∶ 105.
2. 王彩霞， 袁孟彪， 陳靜. 原癌基因產(chǎn)物βcatenin在胃癌組織中的表達 [Ｊ]. 山東醫(yī)科大學(xué)學(xué)報， 2001； 39（2）∶116.
3. Ochiai A, Akimoto S, Shimoyama Y, et al. Frequent loss of alpha catenin expression in scirrhous carcinomas with scattered cell growth [Ｊ]. Jpn J Cancer Res, 1994; 85(3)∶266.
4. Aoki M, Hecht A, Kruse U, et al. Nuclear endpoint of Wnt signaling: neoplastic transformation induced by transactivating lymphoidenhancing factor 1 [Ｊ]. Proc Natl Acad Sci USA, 1999; 96(1)∶139.
5. Qiao Q, Ramadani M, Gansauge S, et al. Reduced membranous and ectopic cytoplasmic expression of betacatenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer [Ｊ]. Int J Cancer, 2001; 95(3)∶194.
6. Karayiannakis AJ, Nakopoulou L, Gakiopoulou H, et al. Expression patterns of betacatenin in in situ and invasive breast cancer [Ｊ]. Eur J Surg Oncol, 2001; 27(1)∶31.
  1. 1. Klppel G, Maillet B. Classification and staging of pancreatic nonendocrine tumors [Ｊ]. Radiol Clin North Am， 1989; 27(1)∶ 105.
  2. 2. 王彩霞， 袁孟彪， 陳靜. 原癌基因產(chǎn)物βcatenin在胃癌組織中的表達 [Ｊ]. 山東醫(yī)科大學(xué)學(xué)報， 2001； 39（2）∶116.
  3. 3. Ochiai A, Akimoto S, Shimoyama Y, et al. Frequent loss of alpha catenin expression in scirrhous carcinomas with scattered cell growth [Ｊ]. Jpn J Cancer Res, 1994; 85(3)∶266.
  4. 4. Aoki M, Hecht A, Kruse U, et al. Nuclear endpoint of Wnt signaling: neoplastic transformation induced by transactivating lymphoidenhancing factor 1 [Ｊ]. Proc Natl Acad Sci USA, 1999; 96(1)∶139.
  5. 5. Qiao Q, Ramadani M, Gansauge S, et al. Reduced membranous and ectopic cytoplasmic expression of betacatenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer [Ｊ]. Int J Cancer, 2001; 95(3)∶194.
  6. 6. Karayiannakis AJ, Nakopoulou L, Gakiopoulou H, et al. Expression patterns of betacatenin in in situ and invasive breast cancer [Ｊ]. Eur J Surg Oncol, 2001; 27(1)∶31.